IBI939
innovent biologics
['nsclc', 'sclc', 'innovent']
innovent presents phase ib clinical data of ibi939 (anti-#tigit mab) in previously untreated pd-l1-selected nsclc at #esmoio22 interestingly that's randomized 2:1 ibi939+simti vs simti alone n=40 tps 50% (27 vs 13)
corr 64.3% vs 57.2% 
Biotellytics / https://t.co/37itIfRolp = business intel service on listed European Bios / Views=mine only, RT-like=/=endorse, no advice. 16y in Tech (chip design)